Denise C Connolly

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. pmc Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53
    Bridget A Quinn
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    PLoS ONE 4:e8404. 2009
  2. pmc Development of a syngeneic mouse model of epithelial ovarian cancer
    Bridget A Quinn
    Women s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    J Ovarian Res 3:24. 2010
  3. ncbi Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007
  4. ncbi RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
  5. pmc Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice
    Harvey H Hensley
    Biological Imaging Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Neoplasia 14:451-62. 2012
  6. pmc Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers
    Shan Deng
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e10277. 2010
  7. pmc Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation
    Shun Liang
    Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 4:e4295. 2009
  8. pmc Network analysis identifies an HSP90-central hub susceptible in ovarian cancer
    Hanqing Liu
    Authors Affiliations Developmental Therapeutics Program, Biostatistics Facility, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania and Synta Pharmaceuticals Corp, Lexington, Massachusetts
    Clin Cancer Res 19:5053-67. 2013
  9. ncbi Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  10. doi Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents
    Denise C Connolly
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Curr Protoc Pharmacol . 2009

Collaborators

Detail Information

Publications14

  1. pmc Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53
    Bridget A Quinn
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    PLoS ONE 4:e8404. 2009
    ..In addition to mutation of BRCA1, mutation of the p53 gene is often found in patients with inherited breast and ovarian cancer syndrome...
  2. pmc Development of a syngeneic mouse model of epithelial ovarian cancer
    Bridget A Quinn
    Women s Cancer Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    J Ovarian Res 3:24. 2010
    ..The objective of this study was to establish an immunocompetent syngeneic mouse model of disseminated epithelial ovarian cancer (EOC) to facilitate laboratory-based studies of ovarian tumor biology and preclinical therapeutic strategies...
  3. ncbi Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007
    ..Our results demonstrate that MRI is well tolerated and can be repeated in serial imaging studies, permitting quantitative analysis of tumor growth and progression and response to therapeutic interventions...
  4. ncbi RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
    ....
  5. pmc Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice
    Harvey H Hensley
    Biological Imaging Facility, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Neoplasia 14:451-62. 2012
    ....
  6. pmc Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers
    Shan Deng
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e10277. 2010
    ..As a novel cancer stem cell marker, ALDH1 can be used for tumors whose corresponding normal tissues express ALDH1 in relatively restricted or limited levels such as breast, lung, ovarian or colon cancer...
  7. pmc Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation
    Shun Liang
    Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 4:e4295. 2009
    ..Our in vivo data suggests that PIK3CA activation is one of the early genetic events in ovarian cancer. However, its role in malignant transformation of ovarian surface epithelium (OSE) is largely unclear...
  8. pmc Network analysis identifies an HSP90-central hub susceptible in ovarian cancer
    Hanqing Liu
    Authors Affiliations Developmental Therapeutics Program, Biostatistics Facility, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania and Synta Pharmaceuticals Corp, Lexington, Massachusetts
    Clin Cancer Res 19:5053-67. 2013
    ..Although there have been numerous efforts to apply protein-targeted agents in EOC, these studies have so far documented little efficacy. Our goal was to identify broadly susceptible signaling proteins or pathways in EOC...
  9. ncbi Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  10. doi Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents
    Denise C Connolly
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Curr Protoc Pharmacol . 2009
    ....
  11. ncbi Activation of cancer-specific gene expression by the survivin promoter
    Rudi Bao
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:522-8. 2002
    ..To investigate whether the survivin promoter controls cancer cell-specific gene expression, we determined whether the survivin gene promoter could regulate reporter gene expression in cancer cell lines and xenografts...
  12. pmc Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization
    Selene Nunez-Cruz
    Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neoplasia 14:994-1004. 2012
    ..Finally, the mouse VEGF(164) transcript was underexpressed in C3(KO) livers compare to C3(WT) livers. Thus, we conclude that complement inhibition blocks tumor outgrowth by altering EC function and VEGF(165) expression...
  13. pmc NEDD9 promotes oncogenic signaling in mammary tumor development
    Eugene Izumchenko
    Program in Molecular and Translational Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Res 69:7198-206. 2009
    ..This study provides the first in vivo evidence of a role for NEDD9 in breast cancer progression and suggests that NEDD9 expression may provide a biomarker for tumor aggressiveness...
  14. ncbi Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
    Denise C Connolly
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:1389-97. 2003
    ....